Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin

N Engl J Med. 2023 Aug 24;389(8):764-766. doi: 10.1056/NEJMc2306105.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal* / pharmacology
  • Antibodies, Monoclonal* / therapeutic use
  • Cells* / classification
  • Cells* / drug effects
  • Humans
  • Immunoconjugates* / pharmacology
  • Immunoconjugates* / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Immunoconjugates
  • polatuzumab vedotin